Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Genetic Counseling × Clear all

Phase

Status

Completed 8 Recruiting 5 Enrolling by invitation 2 Unknown 1 Terminated 1 Suspended 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cancer Risk Syndrome 1

Interventions

pembrolizumab 369 Carboplatin 266 Cyclophosphamide 256 Nivolumab 250 Paclitaxel 210 Specimen Handling 206 Magnetic Resonance Spectroscopy 203 Cisplatin 202 Radiotherapy 187 Dexamethasone 158 Gemcitabine 153 durvalumab 149 Biopsy 144 atezolizumab 133 Lenalidomide 122 Rituximab 116 Doxorubicin 116 Bevacizumab 115 Docetaxel 113 Ipilimumab 109 Radiosurgery 101 Oxaliplatin 99 Capecitabine 99 Radiation 98 Fluorouracil 96 fludarabine 95 Etoposide 94 venetoclax 93 Prednisone 93 Pemetrexed 89

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04323774 2025-12-12

AYA-RISE

Dana-Farber Cancer Institute

Phase NA Active not recruiting

Cancer Risk Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡